Waldenstrom macroglobulinemia

Common Name(s)

Waldenstrom macroglobulinemia

Waldenstrom macroglobulinemia is a chronic, slow-growing lymphoproliferative disorder. It usually affects older adults and is primarily found in the bone marrow, although lymph nodes and the spleen may be involved. Affected individuals have a high level of an antibody called immunoglobulin M (IgM) in their blood, which can cause thickening of the blood (hyperviscosity). Although some individuals initially do not have symptoms and are diagnosed from routine blood work, common symptoms may include weakness, appetite loss and weight loss. Other symptoms may include peripheral neuropathy, fever, Raynaud's phenomenon, and mental status changes. Hyperviscosity of the blood may cause nosebleeds, headaches, dizziness, and blurring or loss of vision. The cause of the condition is not known but environmental, genetic, and viral factors have been suggested. There have been some reports of familial cases suggesting a genetic predisposition. Treatment is often reserved for those with symptoms and may include various medications including corticosteroids, alkylating agents, biologic response modifiers and purine analogues.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Waldenstrom macroglobulinemia" for support, advocacy or research.

International Waldenstrom's Macroglobulinemia Foundation

To offer mutual support and encouragement to the Waldenstrom's macroglobulinemia community and others with an interest in the disease. To provide information and educational programs that address patients' concerns. To promote and support research leading to better treatments and ultimately a cure.

Last Updated: 16 Jul 2014

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Waldenstrom macroglobulinemia" for support, advocacy or research.

International Waldenstrom's Macroglobulinemia Foundation

To offer mutual support and encouragement to the Waldenstrom's macroglobulinemia community and others with an interest in the disease. To provide information and educational programs that address patients' concerns. To promote and support research leading to better treatments and ultimately a cure.

http://www.iwmf.com

Last Updated: 16 Jul 2014

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Waldenstrom macroglobulinemia" returned 129 free, full-text research articles on human participants. First 3 results:

A 44-Year-Old Man with Waldenstrom Macroglobulinemia and Bilateral Maxillary Sinusitis.
 

Author(s): Herman Bagus Trianto, Shinta Oktya Wardhani

Journal: Acta Med Indones. 2016 Jul;48(3):221-227.

 

Waldenstrom macroglobulinemia is a chronic, indolent, lymphoproliferative disorder, which is characterized by the presence of a high macroglobulin (IgM) level, elevated serum viscosity, and the presence of a lymphoplasmacytic infiltrate in the bone marrow. Clinical manifestations ...

Last Updated: 14 Nov 2016

Go To URL
Systemic AL amyloidosis associated with Waldenström macroglobulinemia: an unusual presenting complication.
 

Author(s): Beenu Thakral, Rashmi Kanagal-Shamanna

Journal: Blood. 2016 Jan;127(1):168.

 

Last Updated: 28 Apr 2016

Go To URL
Ibrutinib and idelalisib target B cell receptor- but not CXCL12/CXCR4-controlled integrin-mediated adhesion in Waldenström macroglobulinemia.
 

Author(s): Martin F M de Rooij, Annemieke Kuil, Willem Kraan, Marie José Kersten, Steven P Treon, Steven T Pals, Marcel Spaargaren

Journal: Haematologica. 2016 Mar;101(3):e111-5.

 

Last Updated: 1 Mar 2016

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Waldenstrom macroglobulinemia" returned 19 free, full-text review articles on human participants. First 3 results:

Bing-Neel syndrome, a rare complication of Waldenström macroglobulinemia: analysis of 44 cases and review of the literature. A study on behalf of the French Innovative Leukemia Organization (FILO).
 

Author(s): Laurence Simon, Aikaterini Fitsiori, Richard Lemal, Jehan Dupuis, Benjamin Carpentier, Laurys Boudin, Anne Corby, Thérèse Aurran-Schleinitz, Lauris Gastaud, Alexis Talbot, Stéphane Leprêtre, Béatrice Mahe, Camille Payet, Carole Soussain, Charlotte Bonnet, Laure Vincent, Séverine Lissandre, Raoul Herbrecht, Stéphane Kremer, Véronique Leblond, Luc-Matthieu Fornecker

Journal: Haematologica. 2015 Dec;100(12):1587-94.

 

Central nervous system involvement by malignant cells is a rare complication of Waldenström macroglobulinemia, and this clinicopathological entity is referred to as the Bing-Neel syndrome. There is currently no consensus on the diagnostic criteria, therapeutic approaches and response ...

Last Updated: 2 Dec 2015

Go To URL
Waldenstrom macroglobulinemia: prognosis and management.
 

Author(s): A Oza, S V Rajkumar

Journal:

 

Waldenstrom macroglobulinemia (WM) is a B-cell lymphoplasmacytic lymphoma characterized by monoclonal immunoglobulin M protein in the serum and infiltration of bone marrow with lymphoplasmacytic cells. Asymptomatic patients can be observed without therapy. First-line therapy should ...

Last Updated: 30 Mar 2015

Go To URL
Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus.
 

Author(s): Meletios A Dimopoulos, Efstathios Kastritis, Roger G Owen, Robert A Kyle, Ola Landgren, Enrica Morra, Xavier Leleu, Ramón García-Sanz, Nikhil Munshi, Kenneth C Anderson, Evangelos Terpos, Irene M Ghobrial, Pierre Morel, David Maloney, Mathias Rummel, Véronique Leblond, Ranjana H Advani, Morie A Gertz, Charalampia Kyriakou, Sheeba K Thomas, Bart Barlogie, Stephanie A Gregory, Eva Kimby, Giampaolo Merlini, Steven P Treon

Journal: Blood. 2014 Aug;124(9):1404-11.

 

Waldenström macroglobulinemia (WM) is a distinct B-cell lymphoproliferative disorder for which clearly defined criteria for the diagnosis, initiation of therapy, and treatment strategy have been proposed as part of the consensus panels of International Workshops on WM (IWWM). As ...

Last Updated: 29 Aug 2014

Go To URL
 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in GeneReviews.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Study of ABT-199 (GDC-199) In Patients With Relapsed Or Refractory Waldenström Macroglobulinemia
 

Status: Recruiting

Condition Summary: Waldenstrom Macroglobulinemia

 

Last Updated: 14 Apr 2017

Go to URL
Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström's Macroglobulinemia
 

Status: Recruiting

Condition Summary: Waldenström's Macroglobulinemia

 

Last Updated: 27 May 2015

Go to URL
Comparison of ASCT and Conventional Chemotherapy in High Risk Waldenström Macroglobulinemia
 

Status: Recruiting

Condition Summary: Waldenström Macroglobulinemia

 

Last Updated: 25 Jul 2016

Go to URL